Skip to content

Press Releases

Updates on ProBioGen and currently relevant topics on human biopharmaceuticals, notably on therapeutic proteins and viral vaccines. 

ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic

Berlin, Germany - March 6, 2025 ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop..

Read More

ProBioGen Laboratory Media
CDMO technology transposase antibody cell line development CLD

ProBioGen Enters Agreement with Polpharma Biologics to Provide High-Performance Cell Line Development Services

May 7, 2025

ProBioGen PCLD Supplementierung Zellkulturmedium
CDMO technology antibody GlymaxX commercialization

GlymaxX®-Enhanced Antibody Now Commercially Available for Innovative Cancer Therapy

Apr 17, 2025

Dr. Alfred Merz Appointed Chief Executive Officer of ProBioGen
growth CDMO ceo management

Dr. Alfred Merz Appointed Chief Executive Officer of ProBioGen

Mar 31, 2025

ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
CDMO transposase acromegaly expression system

ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic

Mar 6, 2025

ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
growth CDMO new website

ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio

Feb 4, 2025

ProBioGen Expands Protein and Viral Manufacturing to Drive Continued Growth
growth CDMO

ProBioGen Expands Protein and Viral Manufacturing to Drive Continued Growth

Jan 7, 2025

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
vaccine development license cancer

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Nov 5, 2024

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
CDMO development antibody

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

May 29, 2024

Change in Management
leadership

Change in Management

Apr 30, 2024

ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
partnership multivalent vaccine hemorrhagic fever

ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever

Mar 27, 2024

ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
partnership antibody GlymaxX Marburg Virus

ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology

Mar 13, 2024

ProBioGen was Granted a New Patent for DirectedLuck® Transposase Technology
technology new patent transposase

ProBioGen was Granted a New Patent for DirectedLuck® Transposase Technology

Dec 14, 2023

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
vaccine development license

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

Sep 26, 2023

ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT™
launch lentivirus manufacturing new technology

ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT™

May 17, 2023

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform
manufacturing clinical phase vaccine

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform

May 4, 2023

Press Contact

probiogen-sarah-wandrey

Sarah Wandrey

Corporate Communications

Phone: +49 (0) 30 3229 35 144
Email: press@probiogen.de

ProBioGen News 

Join our news and always be up-to-date.

Subscribe